Pressure BioSciences Inc. PBIO Archives - Page 12 of 22

FridayOct 04, 2019 12:14 pm

Pressure BioSciences Inc. (PBIO) Gains Praise Amid Disclosure of Innovative Research Tool to Aid Gynecological Cancer Diagnosis, Therapy

Pressure BioSciences was described as an integral part of women’s cancer research efforts during a presentation last month at the International Gynecologic Cancer Society conference in Brazil The company’s patented pressure cycling technology provided a key link in a trio of procedures for analyzing biopsied cells Gynecologic cancers are diagnosed in the United States at a rate of nearly 100,000 women per year, and the global gynecological cancer drug market is expected to generate revenues of more than $41.8 billion by 2026 A new, novel workflow for the analysis of proteins from cancer biopsy samples was recently disclosed at a…

FridayOct 04, 2019 9:59 am

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Initiation of Zacks Small Cap Research Coverage

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that Zacks Small Cap Research ("Zacks SCR") has initiated coverage on the company. Zacks SCR coverage maintains a specific focus on small and micro-cap companies that are believed to be undervalued and well-positioned for future growth. Zacks SCR analysts seek to identify and report on these companies, bringing to investors a unique opportunity to gain insight through its high quality (“institutional”) research for the small cap portfolio. To access the PBIO report,…

TuesdayOct 01, 2019 9:52 am

QualityStocksNewsBreaks – Pressure BioSciences Inc.’s (PBIO) PCT Platform Fills Integral Role for Tumor Analyses in Novel Workflow Presented at IGCS

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that its patented pressure cycling technology (“PCT”) platform was featured as an integral part of an innovative new workflow for the analysis of proteins from cancer biopsy samples. The workflow was presented during a plenary session at the Annual Meeting of the International Gynecologic Cancer Society (“IGCS”) on September 21, 2019 in Rio de Janeiro, Brazil. According to the update, Dr. Thomas Conrads, a nationally acclaimed protein chemist and the senior director…

ThursdaySep 26, 2019 12:47 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc.’s (PBIO) Patented PCT Platform Highlighted in 10 Separate Presentations at International Human Proteome Organization World Congress

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that its patented pressure cycling technology (“PCT”) platform was prominently featured at the International Human Proteome Organization World Congress (“International HUPO”) in no less than ten separate presentations from scientists affiliated with seventeen leading research institutions worldwide. “We believe the unique value provided by our PCT platform for cancer research and diagnostics, which was broadly highlighted across ten presentations at this important international human protein conference, will help to accelerate awareness and…

WednesdaySep 25, 2019 1:22 pm

Pressure BioSciences Inc.’s (PBIO) Proprietary Technology Platform Identified as Key Cancer Biomarker Research Element

Independent research carried out by Chinese and Australian scientists shows that the Pressure BioSciences Pressure Cycling Technology (PCT) platform is excellent for the processing of preserved (formalin-fixed paraffin-embedded, or FFPE) and fresh frozen biopsy tissues, which are considered invaluable for discovering cancer biomarkers Such tissues play a pivotal role in cancer research and may potentially contribute to the development of therapies and prevention protocols Cancer research is one of the more rapidly growing sectors making use of PBIO’s technology; to prepare for further expansion in the future, the company has appointed a new, highly experienced chief financial officer The company…

TuesdaySep 24, 2019 12:35 pm

Pressure BioSciences Inc. (PBIO) Issues Update on Guidance for Revenue Growth and Success of Revolutionary CBD Oil Processing System

The company believes that its total revenue will more than double in 2020, led by commercialization of its revolutionary CBD oil nanoemulsification system PBIO’s BaroShear K45, based on the company’s proprietary Ultra Shear Technology (UST) platform, revolutionizes the manufacture of water-soluble, long-term, stable, highly absorbable, nanoemulsified CBD oil The worldwide CBD market is expected to reach $20 billion in sales by 2024, with competition ramping up as CBD manufacturers seek new ways to stand out PBIO has announced three pre-sales of its BaroShear K45 nanoemulsification system for making water-soluble CBD Oil Progress continues on the build-out of its GMP-compliant manufacturing…

WednesdaySep 18, 2019 10:29 am

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Featured on Stock Day with Everett Jolley to Discuss Advancements in Proprietary Platforms

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that its President and CEO Richard T. Schumacher was recently featured on The Stock Day Podcast hosted by Everett Jolley. During the interview, Schumacher discussed PBIO and the company’s recent achievements. “A year ago, PBIO had one revenue-generating division. We now have three, each based on our proprietary PCT, BaroFold, or UST platforms,” PBIO President and CEO Richard T. Schumacher said in the podcast. “Our PCT platform supports our primary business, which…

TuesdaySep 17, 2019 11:40 am

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Adds Daniel J. Shea as Chief Financial Officer at Pivotal Time for Growth

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that Daniel J. Shea has joined the company as its senior vice president and chief financial officer effective Friday, September 13, 2019. In the key leadership position, Shea’s responsibilities will include directing and overseeing all aspects of the company’s finance and administration functions, including financial reporting and analysis; compliance with GAAP and applicable financial and tax reporting laws and rules; forecasting and budgeting; serving as primary liaison with the company’s independent accounting…

TuesdaySep 10, 2019 12:59 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc.’s (PBIO) PCT Platform Identified as Pivotal for Cancer Biomarker Discovery and Potential Use in Clinical Diagnostics

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced the publication of two scientific journal articles led by independent teams of scientists in China and Australia. Per the update, the articles reported excellent results with PBI’s Pressure Cycling Technology (“PCT”) platform in processing preserved formalin-fixed paraffin-embedded (“FFPE”) and fresh frozen biopsy tissue samples for discovery and elucidation of cancer biomarkers, as well as potential use in clinical diagnostics based upon these markers. "It is estimated (Nature volume 448, pages 959–962,…

MondayAug 26, 2019 2:56 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Secures Agreement with Prominent Biotherapeutics Firm

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life-sciences and other industries, recently executed a contract services agreement with a well-known biotherapeutics firm. An article discussing the company reads, “Under the terms of the agreement, the firm will utilize PBIO’s proprietary BaroFold(TM) technology platform to enhance the process manufacturing of one of its candidate protein drugs (http://ibn.fm/aidN2). . . . PBIO’s BaroFold technology platform offers a unique and cost-effective way to address the complex and often-challenging process of manufacturing the recombinant proteins that are required in the development…

Site Search

Company Search

Tag: Pressure BioSciences Inc. PBIO